Actively Recruiting
Strength Training Response of Muscle in GLP-1 Users
Led by Virginia Polytechnic Institute and State University · Updated on 2026-01-21
30
Participants Needed
1
Research Sites
81 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
GLP-1 medication is being prescribed for weight loss. However, GLP-1 medication may adversely affect muscle mass and muscle function. Moreover, any loss of muscle mass or muscle function with GLP-1 treatment may impair balance and increase fall risk. This is a particular concern among older adults already susceptible to the common muscle strength and muscle function loss with age, yet there is little evidence among this population. This study will address a gap in knowledge regarding the effects of GLP-1 treatment on muscle mass, muscle function, and balance/fall risk among adults age 50 and older.
CONDITIONS
Official Title
Strength Training Response of Muscle in GLP-1 Users
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age 50 years or older
- Currently taking GLP-1 medicine (Weygovy or Zepbound) for 1 month or less
- Weight less than 300 pounds
- Passed a health and exercise readiness screening
You will not qualify if you...
- Age under 50 years
- Weight more than 300 pounds
- Diagnosis of osteoporosis
- Active metabolic, neoplastic, or cardiovascular disease
- Unable or unwilling to provide consent
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Virginia Tech
Blacksburg, Virginia, United States, 24061
Actively Recruiting
Research Team
K
Kevin Davy
CONTACT
E
Elaina Marinik
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
PREVENTION
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here